Market Cap 7.50B
Revenue (ttm) 130.13M
Net Income (ttm) -260.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.26%
Debt to Equity Ratio 0.00
Volume 228,100
Avg Vol 800,506
Day's Range N/A - N/A
Shares Out 66.74M
Stochastic %K 27%
Beta 1.96
Analysts Strong Sell
Price Target $139.00

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 264 4280
Fax: 857 264 4299
Address:
222 Berkeley Street, 12th Floor, Boston, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:52 PM
Actionable Trade Alert for $RYTM: Market Context: $RYTM closed at $112.27, showing strength as it trades above its 30-day (MA30) and 50-day (MA50) moving averages. The RSI at 60.7 indicates bullish momentum, but not overbought. Directional Bias: The price is approaching the 60-day high of $122.2, suggesting potential upward movement. The distance from the recent low of $95.27 provides a solid range for potential gains. Trade Plan: - Suggested Entry: $113.00 (slightly above the last close to confirm momentum) - Stop Loss: $108.00 (below MA30 for risk management) - Take Profit Targets: 1. Target 1: $118.00 (4.4% ROI) 2. Target 2: $122.00 (7.8% ROI) 3. Target 3: $131.00 (16.7% ROI) This plan provides a clear pathway to capitalize on upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
FusionPowerF
FusionPowerF Dec. 25 at 10:16 AM
$RYTM Expectations reset as evidence replaces narrative, where each milestone now functions as a credibility checkpoint. Momentum turns durable only after multiple confirmations.
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Dec. 24 at 1:10 PM
$RYTM I’ve had a very good year with this one.
0 · Reply
Doozio
Doozio Dec. 23 at 11:38 PM
Even HRMY is back in $RYTM ENTA 🐒🍌🧠⏰♾️
0 · Reply
Hognose
Hognose Dec. 23 at 2:58 PM
$RYTM buy here.
0 · Reply
Quantumup
Quantumup Dec. 23 at 12:17 PM
Oppenheimer🏁 $AARD Outperform-$35 and said: We initiate coverage with an Outperform rating and a $35 PT as AARD builds a differentiated rare and common obesity franchise-and ahead of next year's key readout. $SLNO $RYTM Oppenheimer added: Lead program is a global Phase 3 trial for Prader-Willi syndrome, a $1B+ US TAM for which favorable safety alone could make ARD-101 competitive to the sole currently approved option. Topline data due 3Q26. AARD is also pursuing several avenues to advance the treatment condition for general obesity, for which injectable GLP-1 drugs—despite their impressive sales growth—are far from perfect and have created opportunities for innovative oral therapeutics that could be used in complement with them or as independent alternatives. Cash runway sufficient to reach key catalysts that we expect to drive share outperformance from current <$200M EV.
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 11:38 AM
HC Wainwright & Co. has adjusted their stance on Rhythm Pharmaceuticals ( $RYTM ), setting the rating to Buy with a target price of 110 → 123.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:48 PM
Actionable Trade Alert for $RYTM: Market Context: $RYTM is currently trading at $111.73, showing a neutral RSI of 53.22, indicating no immediate overbought or oversold conditions. The price is above both the 30-day MA of 104.66 and the 50-day MA of 106.17, suggesting a bullish trend. Directional Bias: Given the current price relative to MAs and the 60-day high of 122.2, we expect upward momentum. The proximity to the 60-day high indicates potential for further gains. Trade Plan: - Suggested Entry: $112.00 - Stop Loss: $106.00 (approximately 5.4% risk) - Take Profit Targets: 1. $117.00 (4.5% gain) 2. $122.00 (8.9% gain) 3. $130.00 (16.3% gain) Target 3 provides an ROI of over 17%, aligning with our objective. Monitor the trade closely and adjust stops as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
stu4
stu4 Dec. 19 at 1:56 PM
$CADL Hahaha..$RYTM …already did this , much quicker because of the CEO !!
1 · Reply
JulianRoss
JulianRoss Dec. 18 at 8:07 PM
$RYTM biotech flagging after a strong leg, if it holds higher lows and reclaims range highs on volume that’s another push setup
0 · Reply
Latest News on RYTM
Rhythm Pharmaceuticals, Inc. - Special Call

Sep 24, 2025, 5:07 PM EDT - 3 months ago

Rhythm Pharmaceuticals, Inc. - Special Call


Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25, 2025, 11:21 AM EST - 10 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:52 PM
Actionable Trade Alert for $RYTM: Market Context: $RYTM closed at $112.27, showing strength as it trades above its 30-day (MA30) and 50-day (MA50) moving averages. The RSI at 60.7 indicates bullish momentum, but not overbought. Directional Bias: The price is approaching the 60-day high of $122.2, suggesting potential upward movement. The distance from the recent low of $95.27 provides a solid range for potential gains. Trade Plan: - Suggested Entry: $113.00 (slightly above the last close to confirm momentum) - Stop Loss: $108.00 (below MA30 for risk management) - Take Profit Targets: 1. Target 1: $118.00 (4.4% ROI) 2. Target 2: $122.00 (7.8% ROI) 3. Target 3: $131.00 (16.7% ROI) This plan provides a clear pathway to capitalize on upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
FusionPowerF
FusionPowerF Dec. 25 at 10:16 AM
$RYTM Expectations reset as evidence replaces narrative, where each milestone now functions as a credibility checkpoint. Momentum turns durable only after multiple confirmations.
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Dec. 24 at 1:10 PM
$RYTM I’ve had a very good year with this one.
0 · Reply
Doozio
Doozio Dec. 23 at 11:38 PM
Even HRMY is back in $RYTM ENTA 🐒🍌🧠⏰♾️
0 · Reply
Hognose
Hognose Dec. 23 at 2:58 PM
$RYTM buy here.
0 · Reply
Quantumup
Quantumup Dec. 23 at 12:17 PM
Oppenheimer🏁 $AARD Outperform-$35 and said: We initiate coverage with an Outperform rating and a $35 PT as AARD builds a differentiated rare and common obesity franchise-and ahead of next year's key readout. $SLNO $RYTM Oppenheimer added: Lead program is a global Phase 3 trial for Prader-Willi syndrome, a $1B+ US TAM for which favorable safety alone could make ARD-101 competitive to the sole currently approved option. Topline data due 3Q26. AARD is also pursuing several avenues to advance the treatment condition for general obesity, for which injectable GLP-1 drugs—despite their impressive sales growth—are far from perfect and have created opportunities for innovative oral therapeutics that could be used in complement with them or as independent alternatives. Cash runway sufficient to reach key catalysts that we expect to drive share outperformance from current <$200M EV.
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 11:38 AM
HC Wainwright & Co. has adjusted their stance on Rhythm Pharmaceuticals ( $RYTM ), setting the rating to Buy with a target price of 110 → 123.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:48 PM
Actionable Trade Alert for $RYTM: Market Context: $RYTM is currently trading at $111.73, showing a neutral RSI of 53.22, indicating no immediate overbought or oversold conditions. The price is above both the 30-day MA of 104.66 and the 50-day MA of 106.17, suggesting a bullish trend. Directional Bias: Given the current price relative to MAs and the 60-day high of 122.2, we expect upward momentum. The proximity to the 60-day high indicates potential for further gains. Trade Plan: - Suggested Entry: $112.00 - Stop Loss: $106.00 (approximately 5.4% risk) - Take Profit Targets: 1. $117.00 (4.5% gain) 2. $122.00 (8.9% gain) 3. $130.00 (16.3% gain) Target 3 provides an ROI of over 17%, aligning with our objective. Monitor the trade closely and adjust stops as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
stu4
stu4 Dec. 19 at 1:56 PM
$CADL Hahaha..$RYTM …already did this , much quicker because of the CEO !!
1 · Reply
JulianRoss
JulianRoss Dec. 18 at 8:07 PM
$RYTM biotech flagging after a strong leg, if it holds higher lows and reclaims range highs on volume that’s another push setup
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 18 at 2:27 PM
$RYTM LETS GOOOOOOO
0 · Reply
Quantumup
Quantumup Dec. 17 at 4:24 PM
Guggenheim⬆️ $RYTM's PT to $140/reit'd at Buy $SLNO $AARD Canaccord Genuity 12/12⬆️PT to $141 from $114, plus added $2.1 B peak sale@ 50% PoS in PWS to its model; reit'd Buy Citizens 12/12⬆️PT to $167 from $141—reit'd Mkt OP/now includes PWS@ 50% POS/peak🇺🇸sales=$700M in '32 Here's what the Analysts had to say:
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:05 PM
Guggenheim has adjusted their stance on Rhythm Pharmaceuticals ( $RYTM ), setting the rating to Buy with a target price of 120 → 140.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:34 AM
Actionable Trade Alert for $RYTM: Market Context: $RYTM is currently trading at $112.45, showing a stable price action with an RSI of 54.28, indicating a neutral to slightly bullish sentiment. The stock is above the 30-day moving average (MA30) of 104.02 and the 50-day moving average (MA50) of 105.7, suggesting a bullish trend. Directional Bias: The price is closer to the 60-day high of 122.2 than the 60-day low of 95.27, reinforcing a bullish outlook. The ATR of 5.7 indicates moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $112.50 - Stop Loss: $107.50 (4% below entry) - Take Profit Targets: 1. $117.50 (4.4% ROI) 2. $122.00 (8.5% ROI) 3. $131.00 (16.5% ROI) This plan provides a clear risk-reward ratio with the potential for over 17% ROI on the third target. Execute with caution and monitor market conditions. https://privateprofiteers.com
0 · Reply
logan_henderson91
logan_henderson91 Dec. 16 at 7:24 PM
$RYTM M⁣a‌i‍n⁣z⁣ ​B​i‌o⁢med​ I⁢ ​l​o‍v⁣e‍ ⁢w⁣h⁠e⁠n‌ ‍t‍h‍e‌ ‌t‌a⁠p‍e⁣ ⁢l⁤o​o⁢k⁤s​ ‍q⁣u​i⁣e⁠t⁤ ‍bu‍t‍ ​t​h⁢e​ ⁢r⁣an⁣ge⁣ i‍s⁤ ‌a⁤l⁢i⁠v‌e‌,‌ ⁠b⁤e⁣c⁤a⁤u⁠s‌e‌ i⁤t⁣ ⁠t​e‍l​l‍s​ ‍m‍e‍ ⁤v⁢o‌l‌a⁢t​il⁣i⁠t​y‌ ​i‌s⁤ ‌t⁢h​e⁢re ⁤w⁣a⁣i​t⁢i‍ng‌ ⁢t⁤o⁢ b​e⁠ ​u‌n​l‌oc⁣k⁢e‌d⁤,⁢ yo⁣u⁣ ‍a​l​r‍e​a⁢d‌y⁢ h⁢a‌v‍e a‍ ⁠1‍.⁤0​2‍0⁢ ​t⁤o⁤ ⁤1⁣.0‌7⁢0​ ‍r⁣an‌g⁠e‍ wi​t⁠h⁤o⁣u⁢t‌ ⁠“⁠c⁠r⁤ow⁤d⁤”⁣ ‌v‍o⁣lu⁣m⁤e⁠,⁤ s⁢o⁢ ⁤i⁤f‌ ‍v‌o⁠l⁤u⁢m⁠e‍ ⁤s​h⁤o⁤w⁣s⁤ ⁢u⁣p⁤ ​t⁣h‌e‍ ‍s‌a⁤m⁠e‍ ⁣r⁣a⁠n⁢g‍e⁣ ‌c‍a⁤n‌ e⁤x⁤p​a‍n‍d⁠,⁤ ⁠a⁤n‌d⁠ ‌m⁢i​c⁤r⁠o⁣caps expand by jumping levels not by creeping, that is the move that creates the FOMO cycle 🔥
1 · Reply
joseph_murphy44
joseph_murphy44 Dec. 16 at 7:13 PM
$RYTM M⁣a‌i‍n⁣z⁣ ​B​i‌o⁤m‌e⁤d⁠ ⁠I⁢ ​l​i‍k⁣e‍ ⁢t⁣h⁠a⁠t‌ ‍t‍h‍e‌ ‌i‌n⁢t‌r‍a⁣d⁣a⁠y‍ ‌s⁤t​r‍u⁤c⁤t‌u‍r​e‌ ⁠i⁢s‍ ‍n⁢o​t⁤ ⁠m⁣e⁠s⁤s⁠y‌,⁤ ⁢1‌.02‍0​ ‍t⁠o​ ⁠1⁢.‌0​7‌0‌ ⁤i‍s‌ a‍ ⁢cl‌e⁤a⁣n⁢ ⁢r‌an⁠g⁢e⁢,⁠ ​t​h​e​ m‍i⁢d⁣po‍i‍n‍t⁤ ⁢i​s​ ​b⁣a‍s‌i​ca⁢l⁢l‌y⁤ ‍w⁠h⁤e‍r⁠e p⁢r⁤i⁠c‌e⁢ ​i⁣s⁤ ⁤s‌i⁤t‍t​i⁠n⁠g⁣, ⁠a⁠n⁤d​ ⁢VW‍A⁢P⁠ ⁠is⁣ ‍ri‍gh​t⁠ ⁤t⁤h​e⁤r‌e,‍ ⁢w⁢h⁤e⁢n‌ ⁣a⁢ ⁣c⁤h⁣a⁤r⁢t⁢ ‌i⁣s‌ ‍t⁢h⁣i⁠s⁢ ⁣“‍o⁤r⁢g⁣a​n⁣i⁢z⁤e‍d‌” ⁤in‍ ​a ‌mi⁠c⁤r​o⁤c​a‍p⁤,⁤ ‍it‍ ​is⁤ ⁢e‍a‍s‌i‍e⁢r‍ f⁤o⁢r⁣ ​m⁠o⁢m⁣e‌nt‌u‍m‌ ​t⁢r⁠a⁠d⁣e⁢r​s​ ‍t⁣o⁤ ⁠latch on because they can define risk, and defined risk is what brings the next wave of buyers 🔥
0 · Reply
PnLBotZoom_1740
PnLBotZoom_1740 Dec. 16 at 5:36 PM
$RYTM biotech flagging after a run, higher lows while volume fades still look like digestion not distribution
0 · Reply
ChrisOptionsFloww4
ChrisOptionsFloww4 Dec. 16 at 12:25 PM
$RYTM biotech with asymmetric profile, sideways now, traders want a high-volume break out of this range
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:06 AM
Actionable Trade Alert for $RYTM: Market Context: $RYTM closed at $113.56, showing strength with an RSI of 62.03, indicating bullish momentum but nearing overbought territory. The 30-day moving average (MA30) at $104.11 and the 50-day moving average (MA50) at $105.14 suggest a strong upward trend, as the price is well above both averages. The 60-day high of $122.20 provides a potential resistance level, while the low of $95.27 indicates a solid support base. Directional Bias: Bullish. The price's proximity to the 60D high and the positive trend in MAs support upward movement, despite the RSI suggesting caution. Suggested Trade Plan: - Entry: $113.56 - Stop Loss: $109.82 (approx. 3% below entry) - Take Profit Targets: 1. $118.00 (4% gain) 2. $122.00 (7.4% gain) 3. $133.00 (17% gain) This plan targets a minimum of 17% ROI on the third target. Monitor closely for any shifts in momentum. https://privateprofiteers.com
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Dec. 15 at 12:01 AM
$RYTM Too many upgrades for this not to head higher.
1 · Reply
abcdzepeda
abcdzepeda Dec. 12 at 8:46 PM
0 · Reply
erevnon
erevnon Dec. 12 at 7:11 PM
Goldman Sachs maintains Rhythm Pharmaceuticals $RYTM at Buy and raises the price target from $141 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply